Option chain shows key data for Icecure Medical's stock options at various strike prices and expiration dates. Traders use this information to analyze potential trades and assess market sentiment for Icecure Medical.

Icecure Medical (NASDAQ:ICCM) Stock, Option Chain

Icecure Medical

Icecure Medical Ltd is a commercial-stage medical device company. The company is engaged in the research, development, and marketing of cryoablation systems and technologies based on liquid nitrogen, or LN2, for treating tumors. Its cryoablation technology is a minimally invasive alternative to surgical intervention, for tumors, including those found in the breast, lungs, kidneys, bones, and other indications.

movers image

News

Pre-Market Outlook

Markets

Movers

Trading Ideas

AMCX

BIMI

BJDX

FLFV

ICCM

KAVL

LRHC

NDRA

NRIX

OVID

SCNI

SVMH

TRNR

VERO

XTLB

ZAPP

Why Nurix Therapeutics Shares Are Trading Higher By Around 12%; Here Are 20 Stocks Moving Premarket

Earnings

Earnings Misses

Penny Stocks

Health Care

Analyst Ratings

General

The Oncology Institute, Inc. (NASDAQ: TOI) came out with a quarterly loss of $0.22 per share versus the Zacks Consensus Estimate of a loss of $0.12. This compares to loss of $0.10 per share a year ago. These figures are adjusted for non-recurring items.

The Oncology Institute, Inc. Reports Q1 Loss, Lags Revenue Estimates

Screenshot 2024-04-26 at 8.22.23 AM

Biotech

New Standard of Care? IceCure Submits Final ICE3 Data To FDA, Minimally Invasive Cryoablation Shows Similar 5-year Recurrence Outcomes To Surgery With Hormone Therapy

Icecure Medical Ltd

Press Releases

Breast Cancer Patients who Underwent IceCure's ProSense® Cryoablation in Japan Reported Significantly Higher Satisfaction than Patients who Underwent Standard of Care Surgery

IceCure Receives Notice of Allowance in China for Novel Cryogenic Pump for Next-Generation Cryoablation Technology

Small Cap

IceCure's ProSense® Cryoablation Featured in Six Studies Presented at St. Gallen International Breast Cancer Conference

IceCure Reports Updated Timeline and Progress with FDA Regarding Marketing Authorization for ProSense® Cryoablation in Early-Stage Breast Cancer

IceCure Medical to Report 2024 Full Year Financial & Operational Results on March 27, 2025

IceCure's ICESECRET Kidney Cancer Cryoablation Study Interim Results Presented at European Association of Urology Conference in Spain: 88.7% Recurrence-Free Rate

IceCure Medical Reports 2024 Financial Results: 42% Growth in ProSense® Cryoablation Sales in North America

IceCure's ProSense® Featured at European Conference on Interventional Oncology with an Emphasis on Breast Cancer Cryoablation

IceCure Exhibits ProSense® & Sponsors Breast Cryoablation Courses at the Society of Breast Imaging Symposium

IceCure Announces Positive FDA Development: Understanding on Path Forward for Marketing Authorization of ProSense® Cryoablation in Women 70+ with Early-Stage Breast Cancer

HC Wainwright & Co.

Alliance Global Partners

Maxim Group

Screenshot 2024-04-12 at 5.32.25 PM

Game-Changing Tumor Freezing Technology Has The Potential To Offer Women First-Ever Minimally Invasive Alternative To Breast Lumpectomy Surgery

Comments

Icecure Medical

Icecure Medical (ICCM) Options

No option chain data available. Please try again later

Connect With Us

About Benzinga

Market Resources

Trading Tools & Education

Ring the Bell